Hoffmann has been vice-chair of Roche since 2006 and a board director since 1996. Among many other roles, he is a trustee of ...

The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...

Roche (OTCQX:RHHBY) has received FDA clearance with a CLIA waiver for its cobas liat sexually transmitted infection, or STI, multiplex assay panels. The tests will be available exclusively in the U.S.

Firefighters in Worcester, Massachusetts had to deal with extreme heat and cold Wednesday morning as temperatures dropped to ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.

Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to ...

The rise of GLP-1s have made treating obesity one of the largest market opportunities in history. It also has reinforced a ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...